Vivos Therapeutics, Inc. (VVOS) earnings
Quarterly results of Vivos Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Vivos Therapeutics, Inc. reported revenue of $5.2M (+34.9% on the same quarter a year earlier) and a net loss of $5.5M.
Diluted earnings per share were -$0.31.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $5.2M | +34.9% | -$5.5M | -$0.31 |
| Q1 FY2026 | $5.1M | +70.5% | -$7.7M | -$0.52 |
| Q4 FY2025 | $3.8M | +3.4% | -$6.9M | - |
| Q3 FY2025 | $6.8M | +75.7% | -$5.4M | -$0.49 |
| Q2 FY2025 | $3.8M | - | -$5M | -$0.55 |
| Q1 FY2025 | $3M | - | -$3.9M | -$0.45 |
| Q4 FY2024 | $3.7M | - | -$2.8M | - |
| Q3 FY2024 | $3.9M | - | -$2.6M | -$0.40 |
Results filings
- Quarterly report 10-Q
- Quarterly report 10-Q
What were Vivos Therapeutics, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Vivos Therapeutics, Inc. reported revenue of $5.2M and a net loss of $5.5M. The figures come from its filing with the SEC.
Is Vivos Therapeutics, Inc.'s revenue growing?
Revenue in Q2 FY2026 was $5.2M, up 34.9% from $3.8M in the same quarter a year earlier.
Get an email when VVOS reports
Follow VVOS and we email you its next results the day they are filed, with the numbers explained.